Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

gram, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a CRL from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011.  In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting.  In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.  In May 2012, Alexza received a second CRL outlining manufacturing deficiencies.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement
This news release and the planned conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certai
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... BEACH, Calif., Jan. 25, 2011 Every business needs a ... others use a differentiation advantage. Hospitals are not immune from ... Dr. Barry Friedberg says if hospitals want ... institute the use of a brain monitor in all surgeries ...
... an innovative medical technology company focused on the treatment ... Relations, LLC of Bridgewater, N.J., as its public relations ... for the Aerocrine brand; most immediately surrounding the NIOX ... available to measure exhaled nitric oxide (eNO) to aid ...
Cached Medicine Technology:If Hospitals Want a Competitive Advantage - Use Brain Monitors in Surgeries Requiring Sedation says Renowned Anesthesiologist 2R&J Public Relations Named Agency of Record for Aerocrine, Inc. 2
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Children who ... risk for complications and potentially even death than ... new study. However, the Johns Hopkins researchers ... The researchers analyzed data on nearly 440,000 ... States underwent over a 22-year period. The ...
(Date:7/11/2014)... Stamford, CT (PRWEB) July 11, 2014 ... – the nation’s only non-profit dedicated exclusively to ... announced that Joshua Corday has joined the organization ... veteran fundraising professional with deep experience securing gifts ... he served as Annual Giving Director for NewYork ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the biggest ... During the past two decades, the world market for ... 12.5% per year), primarily owing to the importance of ... the largest market for disposable medical supplies in the ... position is held by Europe with a 29% market ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Prostate cancer patients are more ... effective treatment and die sooner if they also have ... from more than 41,200 American men who were diagnosed ... followed them through 2009. Nearly 1,900 of the patients ... before their prostate cancer was discovered. "Men with ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Depression May Make It Harder to Beat Prostate Cancer 2
... important regulatory enzyme may slow the loss of brain ... disorders. In a report receiving advance online publication ... (MGH)-based research team reports that increased expression of Sirt1, ... the brain of a mouse model of HD protected ...
... a dentist but not a general healthcare provider, according to an ... Health . The study, conducted by a nursing-dental research team ... proportion of Americans who are seen annually by a dentist but ... suggests dentists can play a crucial role as health care practitioners ...
... Reporter , FRIDAY, Dec. 16 (HealthDay News) -- Not only does ... in their quality of life, new research finds. ... are a lot of benefits that you might not have thought ... you,d have more stress, that quitting would put more stress on ...
... for the treatment of breast cancer has been ... the U.S. as an alternative to standard whole-breast ... 16th in the Journal of the ... APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy ...
... , FRIDAY, Dec. 16 (HealthDay News) -- First responders ... than double the rate of the general U.S. population, new ... 8 in the American Journal of Industrial Medicine , ... the result of their exposure to the toxic dust created ...
... Road Rippers Lightning Rods, Let,s Rock Elmo and the I ... season, parents should ensure that their children don,t risk permanent ... Department of Otolaryngology measured the noise levels of two dozen ... precise gauging in a soundproof booth at UC Irvine Medical ...
Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:NYU study concludes that dentists could screen 20 million Americans for chronic physical illnesses 2Health News:Life After Cigarettes Is Happier: Study 2Health News:Life After Cigarettes Is Happier: Study 3Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:WTC First Responders More Likely to Have Asthma: Study 2Health News:UC Irvine researchers urge caution when buying noisy toys 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
Medicine Products: